Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus LUMISIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus LUMISIGHT.
AMINOHIPPURATE SODIUM vs LUMISIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
LUMISIGHT is a pegolaptamer that binds to and inhibits the vascular endothelial growth factor (VEGF), thereby reducing angiogenesis and vascular permeability in ocular tissues.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
1 mg administered intravenously as a single dose prior to identification of suspected malignant lesions during cystoscopy.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
Terminal elimination half-life is 4-6 hours in patients with normal renal function; prolonged up to 12-18 hours in moderate to severe renal impairment.
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Primarily renal excretion of unchanged drug (60-70%) and hepatic metabolism with biliary/fecal elimination of metabolites (20-25%). Approximately 5-10% is excreted unchanged in feces.
Category C
Category C
Diagnostic Agent
Diagnostic Agent